LUCD
Lucid Diagnostics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.97
▲ 0.01 (0.79%)
MARKET · —
Price
Open
0.99
Prev close
0.96
Day high
0.98
Day low
0.94
Volume
409.95K
Market cap
$184.13M
P/E (TTM)
—
52W range
0.86 – 1.63
Trailing performance
Returnvs SPY
1W
-0.41%
+1.0%
1M
+1.90%
-1.8%
3M
-3.60%
-6.7%
6M
-29.12%
-40.2%
YTD
-11.56%
-23.8%
1Y
-6.41%
-26.4%
3Y
-34.42%
-108.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$184.13M
Enterprise value$174.57M
Revenue (TTM)$5.45M
Gross profit$-1.18M
EBITDA$-49.81M
Net income$-65.01M
EPS (TTM)$-0.41
Free cash flow$-26.43M
Total cash$34.47M
Total debt$24.91M
Book value / share$0.06
Shares outstanding190.95M
Float140.76M
Short % of float7.87%
Dividend yield—
Beta (5Y)1.08
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.03
PEG ratio—
Price / sales—
Price / book16.92
EV / revenue32.06
EV / EBITDA-3.51
Gross margin-21.69%
Operating margin-868.45%
Profit margin0.00%
Return on equity-556.27%
Return on assets-81.63%
Debt / equity227.96
Current ratio1.33
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $4.71M | $4.35M | $2.43M | $377.00K |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$70.57M | -$53.02M | -$52.67M | -$56.17M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$70.57M | -$53.02M | -$52.67M | -$56.17M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.06 | -0.06 | -9.1% |
| Mar 2026 | -0.06 | -0.07 | -10.5% |
| Dec 2025 | -0.09 | -0.10 | -15.4% |
| Sep 2025 | -0.09 | -0.10 | -15.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.06 | 2 | $1.65M | +36.4% |
| Next quarter | -0.05 | 2 | $1.89M | +25.6% |
| Current year | -0.24 | 2 | $6.25M | +32.9% |
| Next year | -0.16 | 4 | $16.71M | +167.3% |
Analyst targets & ownership
Mean target$3.95
High target$9.25
Low target$2.00
Implied upside308.06%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy2 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders26.50%
Held by institutions33.36%
Institutions holding143
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
50.61M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 20, 26 | MATHEIS DENNIS Director |
BUY | 245.00K | $245.27K | Direct |
| Feb 20, 26 | SOKOLOV JACQUE J Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | MCGRATH DENNIS M Chief Financial Officer |
STOCK | 470.00K | $0 | Direct |
| Feb 20, 26 | LAPIDUS STANLEY N Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | PALUMBO JOHN R Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | AKLOG LISHAN Chief Executive Officer |
STOCK | 2.17M | $0 | Direct |
| Feb 20, 26 | COX JAMES L Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | MATHEIS DENNIS Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | WHITE DEBRA JAYNE Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | O'NEIL SHAUN President |
STOCK | 620.00K | $0 | Direct |
| Feb 20, 26 | GORDON MICHAEL ADAM General Counsel |
STOCK | 300.00K | $0 | Direct |
| Aug 20, 25 | MATHEIS DENNIS Director |
BUY | 100.00K | $101.84K | Direct |
| May 22, 25 | MATHEIS DENNIS Director |
BUY | 350.00K | $457.61K | Direct |
| Feb 20, 25 | SOKOLOV JACQUE J Director |
STOCK | 112.80K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AKLOG LISHAN |
Chief Executive Officer | 3.64M | Stock Award(Grant) |
COX JAMES L |
Director | 405.12K | Stock Award(Grant) |
GORDON MICHAEL ADAM |
General Counsel | 1.00M | Stock Award(Grant) |
LAPIDUS STANLEY N |
Director | 337.39K | Stock Award(Grant) |
MATHEIS DENNIS |
Director | 1.03M | Purchase |
MCGRATH DENNIS M |
Chief Financial Officer | 1.81M | Stock Award(Grant) |
O'NEIL SHAUN |
President | 1.45M | Stock Award(Grant) |
PALUMBO JOHN R |
Director | 338.00K | Stock Award(Grant) |
SOKOLOV JACQUE J |
Director | 320.46K | Stock Award(Grant) |
WHITE DEBRA JAYNE |
Director | 235.80K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
0.97
-0.63% from price
SMA 20
0.95
+0.96% from price
SMA 50
0.99
-2.56% from price
SMA 100
1.04
-7.01% from price
SMA 200
1.12
-13.83% from price
EMA 12
0.97
-0.32% from price
EMA 26
0.97
-0.41% from price
EMA 50
0.99
-2.32% from price
RSI (14)
48.6
Neutral
MACD (12,26,9)
-0.00
Hist 0.00
ATR (14)
0.05
5.13% of price
Realised vol 30D
73.0%
Annualised
Bollinger upper
1.02
20, 2σ
Bollinger lower
0.89
20, 2σ
50 / 200 cross
Death
0.99 vs 1.12
Trend bias
Below 200
-13.83%
Risk profile
Beta vs SPY
1.29
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
73.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-40.7%
Peak to trough
Max drawdown 5Y
-94.3%
Peak to trough
ATR 14
0.05
5.13% of price
Beta (reported)
1.08
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript
Motley Fool · 2d ago
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
MarketBeat · 8d ago
PAVmed Inc. Q2 2026 Earnings Call Summary
Moby · 8d ago
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
PR Newswire · 8d ago
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary
Moby · 9d ago
Lucid Diagnostics Inc (LUCD) (Q2 2026) Earnings Call Highlights: Strategic Pivot to High-Value ...
GuruFocus.com · 9d ago
Lucid Diagnostics Q2 Earnings Call Highlights
MarketBeat · 9d ago
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.